---
title: "Vertex Pharmaceuticals Incorporated Says Inaxaplin Reduces UACR By -42.7% At Week 13 In AMKD With Modest Proteinuria"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299770014.md"
datetime: "2026-09-22T12:54:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299770014.md)
  - [en](https://longbridge.com/en/news/299770014.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299770014.md)
generator: "portal-rs"
---

# Vertex Pharmaceuticals Incorporated Says Inaxaplin Reduces UACR By -42.7% At Week 13 In AMKD With Modest Proteinuria

Sept 22 (Reuters) - Vertex Pharmaceuticals Incorporated (VRTX.O) :

-   VERTEX ANNOUNCES POSITIVE RESULTS FROM PHASE 2B AMPLIFIED STUDY OF INAXAPLIN IN ADDITIONAL POPULATIONS OF PEOPLE WITH APOL1-MEDIATED KIDNEY DISEASE (AMKD) AND COMPLETION OF ENROLLMENT IN THE PHASE 2⁄3 AMPLITUDE TRIAL
-   VERTEX PHARMACEUTICALS INCORPORATED - INAXAPLIN REDUCES UACR BY -42.7% AT WEEK 13 IN AMKD WITH MODEST PROTEINURIA
-   VERTEX PHARMACEUTICALS INCORPORATED - INAXAPLIN REDUCES UACR BY -17.3% AT WEEK 13 IN AMKD WITH TYPE 2 DIABETES
-   VERTEX PHARMACEUTICALS INCORPORATED - INAXAPLIN GENERALLY SAFE AND WELL TOLERATED IN BOTH AMKD COHORTS

Source text:

Further company coverage: (VRTX.O)

### Related Stocks

- [VRTX.US](https://longbridge.com/en/quote/VRTX.US.md)

## Related News & Research

- [Vertex says Phase 2b AMPLIFIED study shows inaxaplin cuts proteinuria in APOL1-mediated kidney disease patients with modest proteinuria](https://longbridge.com/en/news/299762830.md)
- [Vertex Touts Encouraging Data From 'Underappreciated' Kidney Drug](https://longbridge.com/en/news/299800601.md)
- [Lilly touts Foundayo advantage over Novo's Ozempic pill in diabetes analysis](https://longbridge.com/en/news/300421791.md)
- [Polymarket Odds: Will MU, FDS Beat Earnings Tomorrow?](https://longbridge.com/en/news/300470494.md)
- [Meta vs. Microsoft: One Hyperscaler Stock Has Room to Grow, the Other Lacks a Catalyst, Says Investor](https://longbridge.com/en/news/300456248.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**